Combined Inhibition of XPO1 and DNA Methylation Exerts Synergistic Effects in DLBCL
Molecular Carcinogenesis · 2025-10 · 64 (10) · 1609-1619
DOI: 10.1002/mc.70014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, online erschienen am 13.07.2025. Verfasst von Qi Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, DNA Methylation, Hydrazines, Receptors, Cytoplasmic and Nuclear. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: The research leading to these results has received funding from National Natural Science Foundation of China (82270211; 82270197; 82470199); Suzhou City Basic….
Abstract (Originalsprache)
Diffuse large B‐cell lymphoma (DLBCL) is an aggressive type of non‐Hodgkin lymphoma characterized by high rates of relapse and limited responsiveness to standard chemotherapy. Selinxor, a selective inhibitor of XPO1, exhibited antitumor activity in various cancers. However, clinical trial results revealed that selinexor monotherapy exhibited unsatisfactory efficacy in DLBCL. Our study indicated that XPO1 expression was increased in DLBCL and was correlated with poor outcomes of DLBCL patients. Comprehensive proteomic and transcriptomics analysis showed that selinexor has significant impacts on various biological processes in DLBCL. Furthermore, we explored combination strategies involving selinexor to enhance DLBCL treatment. We examined the combined effects of selinexor with decitabine (DAC) and lenalidomide (LEN), and found that selinexor exhibited a synergistic effect with DAC against DLBCL. Further analysis revealed that DAC exerted a synergistic antitumor effect with selinexor by reversing the DNMT1 expression and DNA methylation alterations induced by selinexor. Overall, these findings provided valuable insights into the global impact of selinexor on DLBCL. The combination therapy of selinexor and DAC emerges as a highly promising strategy for effectively treating DLBCL, holding great potential for clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
- Suzhou Sano Precision Medicine Ltd., Suzhou, Jiangsu, China.
- Department of Cell Biology, School of Basic Medical Sciences, Soochow University, Suzhou, Jiangsu, China.
ORCID-Profile: Bingzong Li
Förderung
- The research leading to these results has received funding from National Natural Science Foundation of China (82270211; 82270197; 82470199); Suzhou City Basic…
Zitieren
APA
Li, Q., Xue, X., Chen, S., Zhang, X., Zhang, Y., Hu, R., Zhang, X., Qin, L., Chen, M., Zhuang, W., & Li, B. (2025). Combined Inhibition of XPO1 and DNA Methylation Exerts Synergistic Effects in DLBCL. Molecular Carcinogenesis, 64(10), 1609-1619. https://doi.org/10.1002/mc.70014
Vancouver
Li Q, Xue X, Chen S, Zhang X, Zhang Y, Hu R, et al. Combined Inhibition of XPO1 and DNA Methylation Exerts Synergistic Effects in DLBCL. Molecular Carcinogenesis. 2025;64(10):1609-1619. doi:10.1002/mc.70014
BibTeX
@article{Li2025,
author = {Li, Qi and Xue, Xiaofeng and Chen, Si and Zhang, Xinyun and Zhang, Yuchen and Hu, Ruijing and Zhang, Xinyuan and Qin, Linlin and Chen, Menglu and Zhuang, Wenzhuo and Li, Bingzong},
title = {Combined Inhibition of XPO1 and DNA Methylation Exerts Synergistic Effects in DLBCL},
journal = {Molecular Carcinogenesis},
year = {2025},
volume = {64},
number = {10},
pages = {1609--1619},
doi = {10.1002/mc.70014}
}
EUVIMED